Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 12 Dec 2017 Status changed from recruiting to discontinued.
- 01 Aug 2017 Planned End Date changed from 31 Mar 2017 to 31 Mar 2020.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.